Dephosphorylation of Vav is associated with the induction of mouse erythroleukemia cell differentiation: Effects of orthovanadate and levamisole

International Journal of Oncology

Volumn 12, Issue 6, 1998, Pages 1307-1313

  Scher, Barbara M ^a   Wei, Xiao Jun ^a,b   Waxman, Samuel ^a   Scher, William ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Dephosphorylation; Erythroleukemia; Levamisole; Orthovanadate; Vav

Indexed keywords

DIMETHYL SULFOXIDE; ERYTHROPOIETIN RECEPTOR; FRUCTOSE 2,6 BISPHOSPHATE; HEMOGLOBIN; HEXAMETHYLENEBISACETAMIDE; LACTIC ACID; LEVAMISOLE; ORTHOVANADIC ACID; PROTEIN TYROSINE PHOSPHATASE; STAT5 PROTEIN; UNCLASSIFIED DRUG; VAV PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL DIVISION; DEPHOSPHORYLATION; ENZYME ACTIVITY; ERYTHROLEUKEMIA; HEMOGLOBIN SYNTHESIS; HORMONE RECEPTOR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

EID: 0031844721     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.6.1307     Document Type: Article

References (50)

1. Fibach E, Reuben RC, Rifkind RA and Marks PA: Effects of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells. Cancer Res 37: 440-444, 1977.
2. Gusella J, Weil SC, Tsiftsoglou AS, Volloch V, Neumann JR, Keys C and Housman DE: Hemin does not cause commitment of murine erythroleukemia (MEL) cells to terminal differentiation. Blood 56: 481-487, 1980.
3. Kume T, Tsuneizumi K, Watanabe T, Thomas ML and Oishi M: Induction of specific protein tyrosine phosphatase transcripts during differentiation of mouse erythroleukemia cells. J Biol Chem 269: 4709-4712, 1994.
4. Wu H, Scher BM, Chu LC, Leonard M, Olmedo R, Scher GS, Stecker S, Scher W and Waxman S: Reduction in lactate accumulation correlates with differentiation-induced terminal cell division of leukemia cells. Differentiation 48: 51-58, 1991.
5. Scher BM, Chen J, Hellinger N, Scher W and Waxman S: Effects of protein kinase and protein phosphatase inhibitors on the decrease in lactate and the increase in hemoglobin accumulation during mouse erythroleukemia (MEL) cell differentiation. The Sixth Conference on Differentiation Therapy. Mol Cell Differ 1: 381, 1993.
6. Scher BM, Chen J, Fuksina I, Waxman S and Scher W: Induction of erythroid differentiation is associated with inhibition of glycolysis and a decrease in fructose 2,6-bisphosphate levels. Int J Oncol 11: 1135-1140, 1997.
7. Watanabe T, Kume T, Tsuneizumi K, Kondo K, Shiraishi T and Oishi M: Synergistic induction of erythroid differentiation of mouse erythroleukemia (MEL) cell by inhibitors of topoisomerases and protein tyrosine kinases. Exp Cell Res 199: 269-274, 1992.
8. Watanabe T, Kume T and Oishi M: Alteration of phosphotyrosine-containing proteins at the early stage of erythroid differentiation of mouse erythroleukemia (MEL) cells. J Biol Chem 267: 17116-17120, 1992.
9. Scher BM, Chen J, Fuksina I, Hellinger N, Waxman S and Scher W: The phosphatase inhibitors, orthovanadate and levamisole, inhibit induction of erythroid differentiation and abrogate the associated inhibition of glycolysis. Int J Oncol 12: 987-996, 1998.
10. Kume T, Watanabe T, Sanokawo R, Chida D, Nakamura T and Oishi M: Expression of the protein tyrosine phosphatase B2 gene in mouse erythroleukemia cells induces terminal erythroid differentiation. J Biol Chem 271: 30916-30921, 1996.
11. Ihle JN and Kerr IM: Jaks and Stats in signalling by the cytokine receptor superfamily. Trends Genet 11: 69-74, 1995.
12. Li J-P, D'Andrea AD, Lodish HF and Baltimore D: Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature 343: 762-764, 1990.
13. Li JP and Baltimore D: Mechanism of leukemogenesis induced by mink cell focus-forming murine leukemia viruses. J Virol 65: 2408-2414, 1991.
14. Miura O, Miura Y, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN and Aoki N: Induction of tyrosine phosphorylation of Vav and expression of Pim1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood 84: 4135-4141, 1994.
15. Machide M, Mano H and Todokoro K: Interleukin 3 and erythropoietin induce association of Vav with Tec kinase through Tec homology domain. Oncogene 11: 619-625, 1995.
16. Luger SM, Ratajczak J, Ratajczak MZ, Kucynski WI, Di Paola RS, Ngo W, Clevenger CV and Gewirtz AM: A functional analysis of protooncogene Vav's role in adult human hematopoiesis. Blood 87: 1326-1334, 1996.
17. Damen JE, Wakao H, Miyajima A, Krosi J, Humphries RK, Cutler RL and Krystal G: Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J 14: 5557-5568, 1995.
18. Klingmuller U, Bergelson S, Hsiao JG and Lodish HF: Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci USA 93: 8324-8328, 1996.
19. Gobert S, Lacombe C, Gisselbrecht S and Mayeux P: Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STATS activation. EMBO J 15: 2434-2441, 1996.
20. Quelle FW, Wang D, Nosaka T, Thiefelder WE, Stravopodis D, Weinstein Y and Ihle JN: Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol Cell Biol 16: 1622-1631, 1996.
21. Penta K and Sawyer ST: Erythropoietin induces the tyrosine phosphorylation, nuclear translocation and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem 270: 31282-31287, 1995.
22. Chin H, Nakamura N, Kamiyama R, Miyasaka N, Ihle JN and Miura O: Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. Blood 88: 4415-4425, 1996.
23. Friend C, Scher W, Holland JG and Sato T: Hemoglobin synthesis in murine virus-induced leukemia cells in vitro; stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 68: 378-382, 1971.
24. Ohta Y, Tanaka M, Terada M, Miller OJ, Bank A and Marks PA: Erythroid differentiation: murine erythroleukemia cell variant with unique pattern of induction by polar compounds. Proc Natl Acad Sci USA 73: 1232-1236, 1976.
25. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
26. 4. Nature 227: 680-685, 1970.
27. Chrambach A, Reisfeld RA, Wycoff M and Zaccari J: A procedure for rapid and sensitive staining of protein fractionated by polyacrylamide gel electrophoresis. Anal Biochem 20: 150-154, 1967.
28. Katzav S, Cleveland JL, Heslop HE and Pulido D: Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol 11: 1912-1920, 1991.
29. Hanazono Y, Sasaki K, Odai H, Mimura T, Mitani K, Yazaki Y and Hirai H: Tyrosine phosphorylation of the proto-oncogene product Vav and its association with the adapter Grb2/Ash in a human leukemia cell line UT-7. Jpn J Cancer Res 86: 336-341, 1995.
30. Pallard C, Gouilleux F, Charon M, Groner B, Gisselbrecht S and Dusanter-Fourt I: Interleukin-3, erythropoietin and prolactin activate a STAT5-like factor in lymphoid cells. J Biol Chem 270: 15942-15945, 1995.
31. Kovach JS, Svingen PA and Schaid DJ: Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase. J Natl Cancer Inst 84: 515-519, 1992.
32. Van Belle H: Alkaline phosphatase. I. Kinetics and inhibition by levamisole of purified isoenzymes from humans. Clin Chem 22: 972-976, 1976.
33. Ihle JN: STATs: signal transducers and activators of transcription. Cell 84: 331-334, 1996.
34. Klingmuller U, Lorenz U, Cantley LC, Neel BG and Lodish HF: Specific recruitment of SH-FTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80: 729-738, 1995.
35. Chrétien S, Varlet P, Verdier F, Gobert S, Cartron JP, Gisselbrecht S, Mayeux P and Lacombe C: Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STATS activation. EMBO J 15: 4174-4181, 1996.
36. Ye ZS and Baltimore D: Binding of Vav to Grb2 through dimerization of Src homology 3 domains. Proc Natl Acad Sci USA 91: 12629-12633, 1994.
37. Crespo P, Schuebel KE, Ostrom AA, Gutkind JS and Bustelo XR: Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385: 169-172, 1997.
38. Han J, Luby-Phelps K, Das B, Shu X, Xia Y, Mosteller RD, Krishna UM, Falck JR, White MA and Brock D: Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279: 558-560, 1998.
39. Marshall MS: Ras target proteins in eukaryotic cells. FASEB J 9: 1311-1318, 1995.
40. Damen J and Krystal G: Early events in erythropoietin-induced signaling. Exp Hematol 24: 1455-1459, 1996.
41. Ramos-Morales F, Romero F, Schweighoffer F, Bismuth G, Camonis J, Tortolero M and Fischer S: The proline-rich region of Vav binds to Grb2 and Grb3-3. Oncogene 11: 1665-1669, 1995.
42. Vojtek AB and Cooper JA: Rhô family members: activators of MAP kinase cascades. Cell 82: 527-529, 1995.
43. Nigg EA: Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature 386: 779-787, 1997.
44. Gorlich D: Nuclear protein import. Curr Opin Cell Biol 9: 412-419, 1997.
45. Krantz SB and Goldwasser E: Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus. Proc Natl Acad Sci USA 81: 7574-7578, 1984.
46. Mayeux P, Billat C and Jacquot R: Murine erythroleukemia cells (Friend cells) possess high-affinity binding sites for erythropoietin. FEBS Lett 211: 229-233, 1987.
47. Todokoro K, Kanazawa S, Amanuma H and Ikawa Y: Characterization of erythropoietin receptor on erythropoietinunresponsive mouse erythroleukemia cells. Biochim Biophys Acta 943: 326-330, 1988.
48. D'Andrea AD, Lodish HF and Wong GC: Expression cloning of the murine erythropoietin receptor. Cell 57: 277-285, 1989.
49. Hino M, Tojo A, Misawa Y, Hirotoshi M, Takaku F and Shibuya M: Unregulated expression of the erythropoietin receptor gene caused by insertion of spleen focus-forming virus long terminal repeat in a murine erythroleukemia cell line. Mol Cell Biol 11: 5527-5533, 1991.
50. D'Andrea AD: The interaction of the erythropoietin receptor and gp55. Cancer Surv 15: 19-36, 1992.